Publications by authors named "David End"

Claim this Profile
I
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
David End, Arturo Molina, Mary Todd, Michael L Meyers

Cancer Res· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical safety assessment of a synthetic peptide thrombopoietin agonist: effects on platelets, bone homeostasis, and immunogenicity and the implications for clinical safety monitoring of adverse bone effects.
Elaine Knight, Gary Eichenbaum, Verna Hillsamer, Tony Greway, Alfred Tonelli, David End

Int J Toxicol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
Tianbao Lu, Thomas Markotan, Shelley K Ballentine, Edward C Giardino, John Spurlino, David End

J Med Chem· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zarnestra series.
Patrick Angibaud, Laurence Mevellec, Christophe Meyer, Xavier Bourdrez, Patricia Lezouret, David W End

Eur J Med Chem· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets.
Ruisheng Yao, Yian Wang, Yan Lu, William J Lemon, David W End

Carcinogenesis· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations.
Ronald A Lubet, Konstantin Christov, Ming You, Ruisheng Yao, Vernon E Steele, David W End

Mol Cancer Ther· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
Brigitte C Widemann, Wanda L Salzer, Robert J Arceci, Susan M Blaney, Elizabeth Fox, David End

J Clin Oncol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel beta-(imidazol-4-yl)-beta-amino acids: solid-phase synthesis and study of their inhibitory activity against geranylgeranyl protein transferase type I.
Ashis K Saha, David W End

Bioorg Med Chem Lett· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.
Patrick Angibaud, Ashis K Saha, Xavier Bourdrez, David W End, Eddy Freyne

Bioorg Med Chem Lett· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors.
Patrick Angibaud, Xavier Bourdrez, David W End, Eddy Freyne, Michel Janicot

Bioorg Med Chem Lett· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery.
Marc Venet, David End, Patrick Angibaud

Curr Top Med Chem· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors.
Patrick Angibaud, Xavier Bourdrez, Ann Devine, David W End, Eddy Freyne

Bioorg Med Chem Lett· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777.
William T Gunning, Paula M Kramer, Ronald A Lubet, Vernon E Steele, David W End

Clin Cancer Res· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis